Oral Lesions in Patients With Eating Disorders

Status Recruiting

Clinical Trial Summary

Eating disorders (ED) are common among young. Anorexia (AN) and bulimia (BN) are the most prevalent ED. The American Psychiatric Association's guidelines state a 0.3% AN prevalence among young girls and a 0.1 to 4.2% BN prevalence. Men are not excluded: even if ED are more frequent in females (14-18 years), 1 man off to 10 can be diagnosed with ED. Unfortunately, the onset age is decreasing. In the last few years, always more preteens patients are diagnosed with ED: they generally refer a garbled self perception of body image. ED can have oral manifestations, such as: mucosal lesions, dental erosion, glandular hypertrophy, xerostomia and salivary disorders, dental caries These are the most common manifestations observed in patients with eating disorders, after a routine dental visit. There is not strong evidence that dental caries may be directly related to disordered eating habits; as a matter of fact results are controversial. Despite that, all the studies examined agree on the association between signs listed above and food disorders. Univocal percentages have not been reported in the scientific literature. For instance, a systematic review, dated 2016, showed that dental erosion is diagnosed in 45% of ED people, while other studies documented 70% patients affected by erosion. Another example reported is teeth hypersensitivity. According to some studies, 56% of ED patients reported such complaints, instead of other researches documenting 22% hypersensitivity impairment. As for dental caries, results are dissimilar. Authors showed 78% ED subjects diagnosed with dental caries. Other studies reported almost 50% patients with tooth decay, without statistically significant difference in the values between ED people and controls. All these differences are probably due to the different stages of eating disorders and diagnosis, and oral signs found. Different ages are also considered. The primary aim of the study is to evaluate the prevalence of oral cavity lesions among people affected by eating disorders.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05809778
Study type	Observational
Source	IRCCS Burlo Garofolo
Contact	Milena Cadenaro, MD
Phone	+390403785393
Email	milena.cadenaro@burlo.trieste.it
Status	Recruiting
Phase
Start date	July 21, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05656859` - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed	`NCT04085861` - Mental Health in Dancers; an Intervention Study	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Enrolling by invitation	`NCT04174703` - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing	N/A
Terminated	`NCT04278755` - Binge Eating & Birth Control	Phase 2
Withdrawn	`NCT03050632` - Effects of Cognitive and Emotional Functioning on Treatment Outcomes	N/A
Completed	`NCT02484794` - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application	N/A
Completed	`NCT02567890` - Swedish Body Project for Prevention of Eating Disorders	N/A
Completed	`NCT02252822` - Improving Treatment Engagement for Adolescents With Bulimia Nervosa	N/A
Completed	`NCT02021344` - Mental Health First Aid for College Students	N/A
Completed	`NCT00601354` - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder	N/A
Completed	`NCT00418977` - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents	N/A
Completed	`NCT00304187` - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa	Phase 2
Completed	`NCT00733525` - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa	N/A
Active, not recruiting	`NCT04779216` - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa	Phase 3
Completed	`NCT04433663` - Eating Disorders, Self Regulation and Mentalization	N/A
Recruiting	`NCT05509257` - Naltrexone Neuroimaging in Teens With Eating Disorders	Early Phase 1
Completed	`NCT04509531` - Building Resilience in Cyberbullying Victims	N/A
Recruiting	`NCT05730348` - Mealtime Anxiety in Eating Disorders
Enrolling by invitation	`NCT05814653` - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.